サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：悪性中皮腫治療の世界市場- 2023-2030
市場調査レポート
商品コード
1289781

悪性中皮腫治療の世界市場- 2023-2030

Global Malignant Mesothelioma Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
悪性中皮腫治療の世界市場- 2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

悪性中皮腫治療の世界市場は、2022年に2億5,930万米ドルに達し、2030年には最大5億1,270万米ドルに達することで有利な成長を示すと予測されます。世界の悪性中皮腫治療は、予測期間（2023-2030年）に9.1%のCAGRを示すと予想されています。

悪性中皮腫の症例数の増加、がん治療に対する意識の高まり、さまざまな産業におけるアスベストの使用拡大、技術的ブレークスルーの拡大などの主な業界促進要因が、市場の拡大をサポートすると予想されます。

予測期間中、世界の悪性中皮腫治療市場は、高度な治療法の利用可能性から恩恵を受けると予想されます。さらに、悪性中皮腫治療の世界市場は、中皮腫形成の主要な原因である様々な製品および分野でのアスベストによって牽引されると思われます。

市場力学

早期診断・早期治療のための啓発活動の活発化が市場成長を牽引

悪性中皮腫は世界的に一般化しており、早期診断・早期治療のための啓発活動の強化が必要となっています。多くの団体がこの疾患についての認識を高め、アスベストにさらされた従業員が悪性中皮腫のスクリーニング検査を頻繁に受けることを推奨しており、これにより疾患が進行するのを防ぐことができます。このような意識の高まりは、市場全体の成長にプラスの影響を与えると予測されます。

さらに、タバコや喫煙の消費量の増加は、悪性中皮腫治療市場を前進させます。世界の悪性中皮腫市場の企業の大半は、悪性中皮腫に対する多数の薬剤の組み合わせの効果を探るために組織と協力しています。技術特許が乏しいため、多数の企業が様々な組み合わせの薬に焦点を当てた臨床研究を実施しています。

悪性中皮腫の長い潜伏期間が市場成長の妨げになる可能性が高い

悪性中皮腫の潜伏期間が長いこと、初期段階での疾患特異的バイオマーカーの不足、がん治療のための革新的なデバイスの開発と承認が、予測期間を通じて悪性中皮腫治療市場の成長を鈍化させる可能性があります。

COVID-19の影響分析

悪性中皮腫治療の世界市場は、COVID-19の発生による恩恵を受けています。COVID-19の状況について、いくつかのセグメントで医薬品需要の増加が見られました。この業界の製薬企業は、サプライチェーン・マネジメントを大幅に改善し、研究開発能力を高め、製造管理および品質管理への投資を増加させました。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 薬物クラス別スニペット
  • 投与経路別スニペット
  • エンドユーザー別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
      • 悪性中皮腫の潜伏期間の長さ
    • 機会
      • 先端技術の採用が進む
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

第7章 薬剤タイプ別

  • ペメトレキセド
  • シスプラチン
  • カルボプラチン
  • ゲムシタビン
  • ビノレルビン
  • その他

第8章 投与経路別

  • 経口
  • 非経口

第9章 投与経路別

  • 病院
  • がんセンター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • Dr. Reddy's Laboratories,
  • Wellona Pharmaceuticals
  • Bristol-Myers Squibb
  • Novocure
  • Eli Lilly and Company
  • Merck
  • Manus Aktteva Biopharma LLP
  • Pfizer
  • Ono Pharmaceuticals

第13章 付録

目次
Product Code: PH5147

Market Overview

The Global Malignant Mesothelioma Therapeutics Market reached US$ 259.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 512.7 million by 2030. The global malignant mesothelioma therapeutics is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

The main industry drivers, including the rise in malignant mesothelioma instances, rising cancer treatment awareness, expanding use of asbestos in a variety of industries, and expanding technical breakthroughs, are anticipated to support market expansion.

Over the projected period, the global malignant mesothelioma therapeutics market is expected to benefit from the availability of sophisticated treatments. Furthermore, the global market for malignant mesothelioma therapeutics is likely to be driven by asbestos in various products and sectors, which is a key cause of mesothelioma formation.

Market Dynamics

Increased Awareness Campaigns to Diagnose and Treat the Disease at an Earlier Stage will Drive the Market Growth

Malignant mesothelioma is becoming more common worldwide, necessitating increased awareness campaigns to diagnose and treat the disease at an earlier stage. Many groups are raising awareness about the condition and recommending that asbestos-exposed employees get frequent screenings for malignant mesothelioma, which can help prevent the disease from progressing to advanced stages. This increased awareness is projected to impact market growth overall positively.

Furthermore, rising tobacco and smoking consumption propel the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.

The Long Latency Period For Malignant Mesothelioma Is Likely To Hamper The Market Growth

A long latency period for malignant mesothelioma, a lack of disease-specific biomarkers in the early stages, and the development and approval of innovative devices for cancer treatment may slow the growth of the malignant mesothelioma therapeutics market throughout the projection period.

COVID-19 Impact Analysis

The global market for malignant mesothelioma therapeutics has benefited from the COVID-19 outbreak. About the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.

Segment Analysis

Pemetrexed Drug in Drug Class Segment will Dominate in the Market by Capturing 39.1% During the Forecast Period

The preference for combination medicines over monotherapy is one of the key factors that positively influence the Pemetrexed and combination drug type sector. Combination therapies, such as chemotherapy combined with radiation, targeted antibodies, cryotherapy, or other immunotherapies, are anticipated to expand the potential indications for various drugs.

These combination therapies aim to improve survival rates significantly, as evidenced by limited clinical data compared to only surgeries or radiation therapies. Several companies have discovered that multiple pathways in tumor regulation are affected, and as a result, they seek to use combination therapy as a more effective method. These factors are likely to boost the malignant mesothelioma therapeutics market.

Geographical Analysis

North America is the Dominating Region During the Forecast Period

In 2022, the United States is a key participant in this region, accounting for approximately 39.2% of the market. Because of increased awareness about risk factors and diagnostic procedures, the malignant mesothelioma market size in North America is growing faster than in other areas. Advanced healthcare infrastructure is also expected to drive and contribute to the growth of the malignant mesothelioma therapeutics market in North America.

Competitive Landscape

The major global players include: Dr. Reddy's Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer and Ono Pharmaceuticals.

  • Why Purchase the Report?
  • To visualize the global malignant mesothelioma therapeutics market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of malignant mesothelioma therapeutics market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The malignant mesothelioma therapeutics market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End user

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers

Increased awareness campaigns to diagnose and treat the disease at an earlier stage

    • 4.1.2. Restraints
      • 4.1.2.1. The long latency period for malignant mesothelioma
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing adoption of advanced technologies
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Pemetrexed
  • 7.2. Cisplatin
  • 7.3. Carboplatin
  • 7.4. Gemcitabine
  • 7.5. Vinorelbine
  • 7.6. Others

8. By Route of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. By Route of Administration

  • 9.1 Hospitals
  • 9.2 Cancer Centers
  • 9.3 Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%) By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Use
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Dr. Reddy's Laboratories,
  • 12.2. Wellona Pharmaceuticals
  • 12.3. Bristol-Myers Squibb
  • 12.4. Novocure
  • 12.5. Eli Lilly and Company
  • 12.6. Merck
  • 12.7. Manus Aktteva Biopharma LLP
  • 12.8. Pfizer
  • 12.9. Ono Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us